Despite the clinical promise of ICIs, only a small proportion of patients with CI-responsive cancer subtypes benefit from treatment with anti-PD-1, PD-L1, and CTLA4 antibodies because of the high heterogeneity and complexity of cancer and the multiple mechanisms it uses to evade immune surveillance in addition to inhibiting anti-tumor T cell responses (9). This evidence concerns the gene PDCD1 and neoplasm.